Journal of Pharmacological Sciences (Jun 2018)

Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase

  • Mitsuhisa Koga,
  • Yuki Kanaoka,
  • Tetsushi Tashiro,
  • Nagisa Hashidume,
  • Yasufumi Kataoka,
  • Atsushi Yamauchi

Journal volume & issue
Vol. 137, no. 2
pp. 224 – 229

Abstract

Read online

Smoking cessation is the most effective treatment in patients with emphysema and lung inflammation. The aim of the present study was to examine the effect of varenicline, a smoking cessation drug, on emphysema in porcine pancreatic elastase (PPE)-inhaled mice. PPE-inhaled mice were treated with varenicline and an α7 nicotinic acetylcholine receptor (nAChR) antagonist, methyllycaconitine (MLA) for 5 and 21 days. Varenicline markedly ameliorated alveolar expansion and inflammatory response in bronchoalveolar lavage fluid in PPE-inhaled mice. These blocking effects were inhibited by MLA. Our findings demonstrate that varenicline likely has an anti-inflammatory property including reduced inflammatory cell recruitment in lung tissue to protect PPE-induced alveolar expansion via α7 nAChR. Keywords: Varenicline, Emphysema, Inflammatory cells